Evidence map›Paper›PMID 38476004›Full record

ArticleJapanese journal of clinical oncology2024

High-efficiency EGFR genotyping using cell-free DNA in bronchial washing fluid.

Yoshihiko Murata, Yumi Nakajima, Yukio Sato, Nobuyuki Hizawa, Daichi Yamakawa, Daisuke Matsubara, Masayuki Noguchi, Yuko Minami

Open access · hybridAbstract read
In one paragraph

Article in Japanese journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yoshihiko MurataDepartment of Pathology, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.
Yumi NakajimaSchool of Medicine and Health Science, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Yukio SatoDepartment of Thoracic Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Nobuyuki HizawaDivision of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Daichi YamakawaDepartment of Pathology, Naritatomisato Tokushukai Hospital, Tomisato, Chiba, Japan.
Daisuke MatsubaraDepartment of Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Masayuki NoguchiDepartment of Pathology, Naritatomisato Tokushukai Hospital, Tomisato, Chiba, Japan.
Yuko MinamiDepartment of Pathology, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.ORCID 0000-0002-0037-346X
University of Tsukuba · JPUniversity of Tsukuba Hospital · JPShonan Institute of Technology · JPSuita Tokushukai Hospital · JP

Funding

JSPS JP21H04263
6 · The paper itself

Abstract

backgroundEGFR mutation testing is required for treatment of lung adenocarcinoma using epidermal growth factor receptor-tyrosine kinase inhibitor. However, the amounts of tumor tissue or tumor cells obtained by bronchoscopy are often insufficient. Bronchial washing fluid, obtained by lavage with saline after tumor biopsy or brushing, and the supernatant of bronchial washing fluid are thought to contain cell-free DNA that would be potentially applicable for EGFR testing.

methodsFrom among patients with suspected adenocarcinoma or non-small cell lung carcinoma diagnosed from biopsy or surgical specimens at the University of Tsukuba Hospital between 2015 and 2019, cell-free DNAs from 80 specimens of supernatant of bronchial washing fluid (50 with EGFR mutation and 30 with wild type EGFR) and 8 blood serum samples were examined for EGFR mutation using droplet digital PCR.

resultsAmong the 50 patients harboring EGFR mutation, the rate of positivity for cell-free DNA extracted from supernatant of bronchial washing fluid was 80% (40/50). In nine of the EGFR mutation-positive cases, tumor cells were not detected by either biopsy or cytology, but the mutation was detected in four cases (4/9, 44%). Comparison of the cell-free DNA mutation detection rate between supernatant of bronchial washing fluid and blood serum in six cases showed that mutations were detected from the former in all cases (6/6, 100%), but from the latter in only one case (1/6, 17%).

conclusionsUsing supernatant of bronchial washing fluid samples, the detection rate of EGFR mutation was high, and EGFR mutations were detectable even when no tumor cells had been detectable by biopsy or cytology. Supernatant of bronchial washing fluid might be an effective sample source for EGFR mutation testing.

Indexed as

Bronchoalveolar Lavage FluidCell-Free Nucleic AcidsErbB ReceptorsLung NeoplasmsMutationAdenocarcinoma of LungAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDNA Mutational AnalysisFemaleGenotypeGenotyping TechniquesHumansMaleCell-Free Nucleic AcidsEGFR protein, humanErbB Receptorscell-free DNA (cfDNA)droplet digital PCR (ddPCR)EGFR mutationsupernatant of bronchial washing fluid (sBWF)

Identifiers

PMID38476004
PMCPMC11144292
OpenAlexW4392722058

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.